Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

Completed

Phase 1 Results N/A

Summary of Purpose

This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 November 2011.

1 Feb 2011 24 Feb 2011 1 Nov 2011 1 Nov 2011 1 May 2011 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Contacts

  • David Han, MD